Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Kymera Therapeutics, Inc is a biotechnology business based in the US. Kymera Therapeutics shares (KYMR) are listed on the NASDAQ and all prices are listed in US Dollars. Kymera Therapeutics employs 64 staff and has a trailing 12-month revenue of around USD$23.1 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$25.43 - USD$91.92 |
---|---|
50-day moving average | USD$69.6935 |
200-day moving average | USD$50.3683 |
Wall St. target price | USD$77.8 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | N/A |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$23.1 million |
---|---|
Gross profit TTM | USD$-34,224,000 |
Return on assets TTM | 0% |
Return on equity TTM | 0% |
Profit margin | -192.45% |
Book value | N/A |
Market capitalisation | USD$2.2 billion |
TTM: trailing 12 months
There are currently 1.2 million Kymera Therapeutics shares held short by investors – that's known as Kymera Therapeutics's "short interest". This figure is 8% up from 1.1 million last month.
There are a few different ways that this level of interest in shorting Kymera Therapeutics shares can be evaluated.
Kymera Therapeutics's "short interest ratio" (SIR) is the quantity of Kymera Therapeutics shares currently shorted divided by the average quantity of Kymera Therapeutics shares traded daily (recently around 154135.10362694). Kymera Therapeutics's SIR currently stands at 7.72. In other words for every 100,000 Kymera Therapeutics shares traded daily on the market, roughly 7720 shares are currently held short.
However Kymera Therapeutics's short interest can also be evaluated against the total number of Kymera Therapeutics shares, or, against the total number of tradable Kymera Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kymera Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Kymera Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0367% of the tradable shares (for every 100,000 tradable Kymera Therapeutics shares, roughly 37 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Kymera Therapeutics.
Find out more about how you can short Kymera Therapeutics stock.
We're not expecting Kymera Therapeutics to pay a dividend over the next 12 months.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.